Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies

  • Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72. doi: 10.1016/j.bmcl.2006.10.093.
Mei Liu  1 ,  Sanyi Wang ,  Jill E Clampit ,  Rebecca J Gum ,  Deanna L Haasch ,  Cristina M Rondinone ,  James M Trevillyan ,  Cele Abad-Zapatero ,  Elizabeth H Fry ,  Hing L Sham ,  Gang Liu
Affiliations
  • 1. Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6098, USA. [email protected]
PMID: 17107797 DOI: 10.1016/j.bmcl.2006.10.093
Abstract

A new series of 4-anilinopyrimidines has been synthesized and evaluated as JNK1 inhibitors. SAR studies led to the discovery of potent JNK1 inhibitors with good enzymatic activity as well as cellular potency represented by compound 2b. Kinase selectivity profile and the crystal structure of 2b are also described.

Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15737
    DB07268
    99.04%, JNK Inhibitor
    target: JNK
    Research Areas: Cancer